| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8508626 | Actualités Pharmaceutiques | 2017 | 5 Pages |
Abstract
Incretins constitute a relatively recent therapeutic option for treating type 2 diabetes. The lack of data as to their benefit and their long-term tolerance still limits their use. They are consequently recommended as a second-line treatment and in combination with other therapies. The pharmacist must ensure the prescription instructions for incretin mimetics and gliptins are respected and support the patient in the management of his or her advanced diabetes, notably through therapeutic education.
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Drug Discovery
Authors
Sébastien (Professeur des Universités),